TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24510678
Drug: Cangrelor (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor (specific receptor antagonist for P2Y12)
Study: 17922978
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 200 microg once daily in the evening
Study: 17922978
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 400 microg twice daily (BID)
Study: 17922978
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 200-400 microg once daily
Study: 15695959
Drug: Physical therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapies and shoulder arthrography with intra-articular steroid
Study: 15695959
Drug: Physical therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapies alone
Study: 10047935
Drug: 2.5 mg/d
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/d of deprenyl
Study: 10047935
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of deprenyl
Study: 7267221
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Blood phenylalanine target 1.0 to 5.4 mg/100 ml
Study: 7267221
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Blood phenylalanine target 5.5 to 9.9 mg/100 ml
Study: 9108785
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups
Study: 22704274
Drug: Treatment factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment factors
Study: 30102967
Drug: Lurasidone 80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 80-120 mg/day
Study: 24170180
Drug: Lurasidone 20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20-60 mg/day and 80-120 mg/day
Study: 22424912
Drug: Immediate-release hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release hydromorphone (IR) 5 times/day
Study: 22424912
Drug: Once-daily hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily hydromorphone extended-release (ER) at full dose
Study: 22424912
Drug: Once-daily hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily hydromorphone extended-release (ER) at half dose
Study: 17226906
Drug: Rifaximin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (400 mg bid for 7 d every month) plus dietary fiber supplementation (at least 20 gr/d)
Study: 15128011
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (estrogen-progestin combination)
Study: 9638982
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for gastrointestinal bleeding
Study: 24590644
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenously every 4 weeks)
Study: 22749044
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg once daily) + Salmeterol (50 μg twice daily) (T + S)
Study: 22749044
Drug: Salmeterol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol + Fluticasone (50/500 μg twice daily) (S + F)
Study: 16319156
Drug: Intraarticular sodium
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular sodium hyaluronate (SH) 10 mg
Study: 16319156
Drug: Intraarticular glucocorticoids
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular glucocorticoids (triamcinolone acetonide; TA) 10 mg
Study: 12873934
Drug: Alprostadil 0.2
Normalized name: alprostadil 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil 0.2 micro g. kg(‐1). min(‐1) (20 mL/h) for 60 min
Study: 12873934
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 20 mL/h for 60 min (Control)
Study: 10526249
Drug: Finasteride 5mg
Normalized name: FINASTERIDE 5MG TAB
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride 5mg once daily for 12 months
Study: 10526249
Drug: Flutamide 250mg
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 250mg twice daily for 12 months
Study: 8879439
Drug: Gemfibrozil (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (two 600-mg tablets once per day for 8 weeks)
Study: 8503391
Drug: Cisapride (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (15 mg/day for 14 days)
Study: 3689013
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg intrarectally every 6-8 hours until postoperative day 3)
Study: 31092654
Drug: 5% aciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% aciclovir cream
Study: 21788129
Drug: PSA screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA screening with a cut-off of 3.0-4.0 ng/ml at a 2-7 year interval
Study: 16960268
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg iv with epidural injection of 0.25% bupivacaine 8 mL and normal saline 2 mL (Control)
Study: 16960268
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 mL iv with epidural injection of 0.25% bupivacaine 8 mL and dexamethasone 5 mg in normal saline 2 mL (D1)
Study: 16960268
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 mL iv with epidural injection of dexamethasone 5 mg in normal saline 10 mL (D2)
Study: 15485402
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Framingham score and urinary albumin excretion
Study: 11011783
Drug: 8.5 g
Normalized name: LACTIC ACID 28.5 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.5 g of supplemental arginine
Study: 11011783
Drug: 17 g
Normalized name: lancets 17 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 g of supplemental arginine
Study: 11011783
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of supplemental arginine (Control)
Study: 11011783
Drug: 8.5 g
Normalized name: LACTIC ACID 28.5 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.5 g and 17 g of supplemental arginine
Study: 8707022
Drug: Propafenone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (mean daily dose of 13 ± 1.5 mg/Kg; Group A: 102 patients)
Study: 8707022
Drug: Sotalol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (mean daily dose of 3 ± 0.4 mg/Kg; Group B: 106 patients)
Study: 22817664
Drug: Low-intensity, pulsed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity, pulsed, electromagnetic fields (PEF) treatment for 10 minutes (mean intensity 1.5 mW)
Study: 22817664
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 10 minutes
Study: 21059637
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HD-CT) with one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell infusion
Study: 21059637
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose BEP (cisplatin, etoposide, and bleomycin)
Study: 15111618
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HD-CT)
Study: 21059637
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose BEP
Study: 19717851
Drug: Beta-blocker continuation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker continuation
Study: 19717851
Drug: Beta-blocker discontinuation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker discontinuation
Study: 14766592
Drug: Baker's yeast
Normalized name: Baker's yeast proteinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baker's yeast bread containing ca. 2 g of gluten.
Study: 11701466
Drug: Niacin-ER (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin-ER (1 g)
Study: 11701466
Drug: Niacin-ER (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin-ER (2 g)
Study: 11701466
Drug: Gemfibrozil (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1.2 g)
Study: 7983641
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prednisone (5 to 10 mg/day)
Study: 7983641
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prednisone
Study: 2954800
Drug: Pure porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure porcine insulin
Study: 3185283
Drug: Mixed bovine/porcine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed bovine/porcine insulin
Study: 21193190
Drug: LT4 treatment
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 treatment (50 μg administered from the first day of controlled ovarian stimulation for IVF/ICSI)
Study: 14632720
Drug: Insulin/gliclazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/gliclazide
Study: 14632720
Drug: Insulin/repaglinide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/repaglinide
Study: 10939691
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA) with propofol
Study: 10437193
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupuncture, pilose antler essence injection to acupoints, and oral administration of Chinese materia medica
Study: 3534849
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg/Hydrochlorothiazide 12.5 mg once daily (o.d.)
Study: 3534849
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg/Hydrochlorothiazide 25 mg once daily (o.d.)
Study: 26121892
Drug: Peritonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration of ketamine (0.5 mg/kg)
Study: 25059854
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg orally)
Study: 22482373
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine 8 mcg/kg (N8)
Study: 22482373
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine 4 mcg/kg (N4)
Study: 21490978
Drug: Rapid maxillary
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid maxillary expansion (RME) and face mask therapy
Study: 17272491
Drug: alpha-tocopherol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (500 mg/day)
Study: 17272491
Drug: mixed tocopherols
Normalized name: vitamin E (as mixed tocopherols)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mixed tocopherols (500 mg/day)
Study: 15655442
Drug: Comfort care
Normalized name: Carmex Comfort Care Berry SPF 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comfort care (swaddled, held, and given 24% sucrose solution)
Study: 7800307
Drug: Dehydroepiandrosterone sulfate
Normalized name: Dehydroepiandrosterone sulfate
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydroepiandrosterone sulfate (DHAS) 200 mg intravenous in 20 mL of 5% dextrose
Study: 7800307
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 mL of 5% dextrose)
Study: 2347955
Drug: Ceftibuten 200
Normalized name: ceftibuten 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 200 mg taken orally twice daily (7:00 AM and 7:00 PM) during the trial period.
Study: 2347955
Drug: Theophylline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (4 mg/kg) administered intravenously without ceftibuten treatment.
Study: 659922
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml intramuscularly (im) administered human diploid cell rabies virus vaccine
Study: 659922
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml intradermally (id) administered human diploid cell rabies virus vaccine
Study: 659922
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of vaccine administered by subcutaneous or id route
Study: 27164220
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Theacrine (TeaCrine®)
Study: 27164220
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Theacrine (TeaCrine®)
Study: 22972745
Drug: TCZ 4
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TCZ 4 mg/kg + DMARDs
Study: 22972745
Drug: TCZ 8
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TCZ 8 mg/kg + DMARDs
Study: 22972745
Drug: TCZ 8
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TCZ 8 mg/kg monotherapy
Study: 19767814
Drug: Carbohydrate-protein mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-protein mixture (9% sucrose solution + 3% whey protein isolate, 0.4 g.kg‐1 body mass.h‐1)
Study: 19767814
Drug: Carbohydrate alone
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate alone (9% sucrose solution, 1.2 g.kg‐1 body mass.h‐1)
Study: 17582067
Drug: Paromomycin (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin (11 mg/kg intramuscularly daily for 21 days)
Study: 17582067
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (1 mg/kg intravenously every other day for 30 days)
Study: 15363822
Drug: Amlodipine besylate/benazapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besylate/benazapril (force titrated to 5/40 mg)
Study: 15363822
Drug: Benazapril/hydrochlorothiazide (force
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg)
Study: 9551418
Drug: Bicarbonate (38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate (38 mM) solution
Study: 9551418
Drug: Bicarbonate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate (25 mM)/lactate (15 mM) solution
Study: 9551418
Drug: Control lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control lactate (40 mM) solution
Study: 7846213
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 + 50 mg)
Study: 3214495
Drug: Lomefloxacin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 100 mg
Study: 3214495
Drug: Lomefloxacin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 200 mg
Study: 3214495
Drug: Lomefloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 600 mg
Study: 3214495
Drug: Lomefloxacin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 800 mg
Study: 30870203
Drug: Zolpidem (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (sustained-release 12.5 mg)
Study: 30870203
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg IR) plus zolpidem (10 mg)
Study: 29035169
Drug: Psychoeducation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducation intervention for patients preparing for HCV treatment
Study: 29035169
Drug: Consistent abstinence
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent abstinence from alcohol, drugs, and smoking
Study: 29035169
Drug: Consistent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent use of alcohol, drugs, and smoking
Study: 29035169
Drug: Achievement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achievement of abstinence after study entry for alcohol, drugs, and smoking
Study: 25698120
Drug: Need-based nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Need-based nutritional intervention (50 g/day soy-protein-based nutritional supplement)
Study: 16206100
Drug: Iron sulfate
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron sulfate combined with a 2-week course of lansoprazole, clarithromycin, and amoxicillin
Study: 16206100
Drug: Metronidazole-based quadruple
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole-based quadruple therapy (re-treatment)
Study: 12800480
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (insulin infusion tailored to control blood glucose levels in the range 80-110 mg/dL)
Study: 10235612
Drug: Interferon retreatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon retreatment at original dose (group A1: 234 MU, 11 patients; group B1: 468 MU, 10 patients)
Study: 10235612
Drug: Interferon retreatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon retreatment at twice the original dose (group A2: 468 MU, 11 patients; group B2: 936 MU, 10 patients)
Study: 10235612
Drug: Increasing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the dose of interferon above that of the first cycle
Study: 1898811
Drug: iohexol 180
Normalized name: iohexol 180 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 180 mg l/ml
Study: 1898811
Drug: iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 300 mg l/ml
Study: 6549746
Drug: pH-sensitive enteric
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-sensitive enteric coated pancreatic enzyme preparation
Study: 6549746
Drug: Conventional pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pancreatic enzyme preparation
Study: 22230921
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral SAL (6 mg)
Study: 22230921
Drug: Short-term oral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oral SAL (12 mg day(‐1) for 3 weeks)
Study: 20845112
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Stress Management plus Expressive Supportive Therapy (CBSM+)
Study: 17643995
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1 g) administered 15 min before the end of surgery and every 6h for 72 h
Study: 12794781
Drug: Proton-pump inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitors with COX-2 NSAIDs
Study: 11056128
Drug: Triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin acetate 15 microg daily
Study: 11056128
Drug: Triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin acetate 50 microg daily
Study: 11056128
Drug: Triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin acetate 100 microg daily
Study: 9366786
Drug: Graded-exercise test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded-exercise test (G-test)
Study: 30586005
Drug: TX-001HR (1/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (1/100 mg)
Study: 30586005
Drug: TX-001HR (0.5/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (0.5/100 mg)
Study: 30586005
Drug: TX-001HR (0.5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (0.5/50 mg)
Study: 30586005
Drug: TX-001HR (0.25/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (0.25/50 mg)
Study: 30586005
Drug: TX-001HR (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (all doses)
Study: 11352963
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine and mitoxantrone (HAM)
Study: 26859081
Drug: Standard-dose cytarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cytarabine, daunorubicin and 6-thioguanine (TAD)
Study: 22469638
Drug: Fentanyl (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1.5 µg/kg)
Study: 22469638
Drug: Buprenorphine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (1.5 µg/kg)
Study: 22469638
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fentanyl (0.75 µg/kg) and buprenorphine (0.75 µg/kg)
Study: 20681275
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin Pill (SXBXP) administered at 2 pills, three times a day for at least 6 months, in addition to conventional therapy.